Affordable Access

Adefovir dipivoxil (Preveon) expanded access restrictions being eased.

Authors
  • James, J S
Type
Published Article
Journal
AIDS treatment news
Publication Date
Feb 06, 1998
Issue
No 288
Pages
4–5
Identifiers
PMID: 11365045
Source
Medline
License
Unknown

Abstract

Gilead Sciences is removing the CD-4 and viral load requirements for people to enter its expanded access program for adefovir dipivoxil (PREVEON). The program changes must be approved by the Food and Drug Administration (FDA). Exceptions are already being made for people who take either efavirenz (Sustiva) or abacavir (1592U89) so they can begin two or three new drugs at once in case of current treatment failure. Adefovir, taken once a day, lowers viral loads, may have fewer resistance problems, and is also active against many herpes viruses. Current clinical trials are determining the best way to use adefovir in combination therapy with other antiretrovirals.

Report this publication

Statistics

Seen <100 times